SuperiorMed and Nasdaq SPAC Starry Sea Sign Business-Combination Agreement

SuperiorMed Holdings Limited has signed an agreement to combine with Nasdaq-listed special purpose acquisition company Starry Sea Acquisition Corp, setting out a two-step merger that is intended to leave SuperiorMed under a newly public Cayman Islands parent. The agreement was signed on August 22, according to an announcement issued by the companies, and both boards have approved the proposed combination.

The announcement establishes the legal structure of the deal but leaves several of its most important financial terms for later filings. It does not disclose a valuation for SuperiorMed, an exchange ratio, the expected ownership split of the combined company, a minimum-cash condition, a PIPE financing commitment or a target closing date. Those omissions mean investors cannot yet determine the implied equity value of SuperiorMed or the dilution that Starry Sea shareholders could face if the merger closes.

Two-step merger would put SuperiorMed under a new listed parent

Under the agreed structure, Starry Sea would first merge with and into SuperiorMed Healthcare Group, a Cayman Islands company that is currently a wholly owned subsidiary of the SPAC. SuperiorMed Healthcare Group would survive that step and become the publicly traded parent. At the same time, SuperiorMed Healthcare MergerCo, another subsidiary created for the combination, would merge into SuperiorMed Holdings Limited, leaving SuperiorMed as a wholly owned subsidiary of the listed parent.

SuperiorMed shareholders are due to receive ordinary shares of the new parent when the merger becomes effective. Certain SuperiorMed shareholders would be subject to a 180-day lock-up after closing, subject to specified exceptions, while holders of Starry Sea securities would also receive ordinary shares of the parent. The announcement does not state how many shares either group would receive, so the relative ownership percentages remain unknown.

The operating business is centered in Dubai. SuperiorMed’s official website describes a healthcare platform focused on longevity, preventive care and personalized wellness services in the United Arab Emirates. The merger announcement says SuperiorMed Holdings is the parent of SuperiorMed Healthcare Management FZ-LLC, which in turn owns two UAE operating subsidiaries, with one of those businesses also operating an additional branch. The group says its activities include clinic and wellness-facility management, associated clinical operations, patient-referral coordination and health-tourism services.

That business profile gives Starry Sea an operating healthcare target after more than a year as a listed shell company. The proposed combination, however, is not complete. Closing requires approvals from shareholders of both Starry Sea and SuperiorMed, required regulatory clearances, effectiveness of a registration statement containing a proxy statement and prospectus, and approval of the combined company’s listing application by the relevant stock exchange.

Starry Sea brings a $59.3 million trust balance, subject to redemptions

Starry Sea raised $57.5 million in its August 2025 initial public offering by selling 5.75 million units at $10 each. Its latest quarterly filing with the U.S. Securities and Exchange Commission showed $59.34 million of cash and investments in its trust account at June 30, 2026, reflecting the original offering proceeds and subsequent interest.

The trust balance should not be treated as cash that will automatically flow to SuperiorMed at closing. Starry Sea’s 5.75 million public shares carry redemption rights, allowing investors to take back their share of the trust in connection with a shareholder vote or other qualifying event. The June-quarter balance sheet classified roughly $57.08 million as ordinary shares subject to possible redemption. The amount ultimately available to a combined company therefore depends on how many public shareholders choose to redeem and on any financing terms added before closing.

Outside the trust account, Starry Sea reported just $6,081 of cash at June 30 and a working-capital deficit of $158,336. It also disclosed $198,432 outstanding under a related-party promissory note. The SPAC said it expects to keep incurring professional and deal-related costs as it works toward a business combination, and its filing notes that additional financing may be needed if redemptions are high or the chosen combination requires more capital.

Timing also matters. Starry Sea’s filings give the company 15 months from the August 2025 closing of its IPO to complete an initial business combination unless the deadline is extended. If it cannot complete a deal within the permitted period and no extension is obtained, the SPAC would be required to redeem its public shares and liquidate. The new SuperiorMed agreement therefore gives Starry Sea a signed target, but it does not remove the execution risk attached to shareholder approvals, redemptions, regulatory review and final financing.

The SuperiorMed agreement follows an earlier health-sector target that fell away

SuperiorMed is not Starry Sea’s first announced healthcare target. In September 2025, the SPAC entered a letter of intent with Forever Young International Limited, a health-industry business that provided management and support services to medical institutions in China. That earlier proposal contemplated a pre-money equity value of about $750 million to $900 million, subject to due diligence.

The Forever Young letter of intent expired on January 12, 2026 without a definitive agreement, and Starry Sea later told the SEC that it did not intend to proceed. The SuperiorMed agreement is materially further along because the parties have now signed a definitive merger agreement and obtained board approvals. Even so, the valuation range attached to the abandoned Forever Young proposal should not be used as a proxy for SuperiorMed. The companies have not disclosed a comparable valuation for the new target.

The next important disclosure is expected to be Starry Sea’s Form 8-K containing a fuller description of the merger agreement and a copy of the agreement itself. A subsequent registration statement and proxy materials should provide the information that is missing from the initial announcement, including the share-exchange mechanics, ownership percentages, detailed financial statements for SuperiorMed, redemption assumptions, any outside financing and the conditions that could allow either side to walk away.

Until those filings arrive, the central development is narrower: Starry Sea has secured a definitive agreement with SuperiorMed and created a path for the Dubai healthcare business to become publicly traded, but the economics of that path have not yet been disclosed in enough detail to value the proposed combination.